文献速递心境障碍

All of Us研究:新冠疫情期间日常歧视与抑郁症状及自杀意念的关联

Association of Everyday Discrimination With Depressive Symptoms and Suicidal Ideation During the COVID-19 Pandemic in the All of Us Research Program.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

歧视超过每周一次时,中重度抑郁症状 odds 增加17.68倍(95%CI 13.49-23.17),自杀意念 odds 增加10.76倍(95%CI 7.82-14.80)。

要点

  • 歧视水平越高,中重度抑郁症状和自杀意念的 odds 越高,呈剂量反应关系。
  • 歧视超过每周一次时,中重度抑郁症状 odds 增加17.68倍(95%CI 13.49-23.17)。
  • 歧视超过每周一次时,自杀意念 odds 增加10.76倍(95%CI 7.82-14.80)。

核心结论

  • 在大型多样本中,歧视水平升高与中重度抑郁症状的 odds 升高相关。
  • 当歧视主要原因为种族、血统或民族出身时,西班牙裔或拉丁裔参与者在全部3个时间点该关联更强,非西班牙裔亚裔参与者在2020年5月和6月该关联更强。

研究设计与样本

  • 使用疫情期间早期重复评估的混合效应模型分析歧视与抑郁症状及自杀意念的关联,并应用逆概率权重校正自愿完成调查的非随机概率。

主要发现

  • 歧视水平升高与中重度抑郁症状及自杀意念的 odds 显著增加相关。
  • 呈剂量反应关联:歧视超过每周一次时,中重度抑郁症状 odds 增加17.68倍(95%CI 13.49-23.17;P<.001),自杀意念 odds 增加10.76倍(95%CI 7.82-14.80;P<.001)。
  • 当歧视主要原因为种族、血统或民族出身时,西班牙裔或拉丁裔参与者在全部3个时间点抑郁症状关联更强,非西班牙裔亚裔参与者在2020年5月和6月关联更强。
  • 高水平歧视与中重度抑郁症状的关联强度与大流行前心境障碍诊断史的关联强度相当。

关键数值与推荐

  • 暴露和结局分别使用日常歧视量表和9项患者健康问卷(PHQ-9)评估。
  • PHQ-9评分≥10分为中重度抑郁症状,PHQ-9第9项任何阳性反应视为存在自杀意念。

临床怎么用

  • 在临床评估中,可将日常歧视经历作为疫情期间抑郁症状和自杀意念的相关因素加以关注。
  • 原文未给出基于歧视筛查的具体临床干预推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The COVID-19 pandemic has coincided with an increase in depressive symptoms as well as a growing awareness of health inequities and structural racism in the United States. OBJECTIVE: To examine the association of mental health with everyday discrimination during the pandemic in a large and diverse cohort of the All of Us Research Program. DESIGN, SETTING, AND PARTICIPANTS: Using repeated assessments in the early months of the pandemic, mixed-effects models were fitted to assess the associations of discrimination with depressive symptoms and suicidal ideation, and inverse probability weights were applied to account for nonrandom probabilities of completing the voluntary survey. MAIN OUTCOMES AND MEASURES: The exposure and outcome measures were ascertained using the Everyday Discrimination Scale and the 9-item Patient Health Questionnaire (PHQ-9), respectively. Scores for PHQ-9 that were greater than or equal to 10 were classified as moderate to severe depressive symptoms, and any positive response to the ninth item of the PHQ-9 scale was considered as presenting suicidal ideation. RESULTS: A total of 62 651 individuals (mean [SD] age, 59.3 [15.9] years; female sex at birth, 41 084 [65.6%]) completed at least 1 assessment between May and July 2020. An association with significantly increased likelihood of moderate to severe depressive symptoms and suicidal ideation was observed as the levels of discrimination increased. There was a dose-response association, with 17.68-fold (95% CI, 13.49-23.17; P < .001) and 10.76-fold (95% CI, 7.82-14.80; P < .001) increases in the odds of moderate to severe depressive symptoms and suicidal ideation, respectively, on experiencing discrimination more than once a week. In addition, the association with depressive symptoms was greater when the main reason for discrimination was race, ancestry, or national origins among Hispanic or Latino participants at all 3 time points and among non-Hispanic Asian participants in May and June 2020. Furthermore, high levels of discrimination were as strongly associated with moderate to severe depressive symptoms as was history of prepandemic mood disorder diagnosis. CONCLUSIONS AND RELEVANCE: In this large and diverse sample, increased levels of discrimination were associated with higher odds of experiencing moderate to severe depressive symptoms. This association was particularly evident when the main reason for discrimination was race, ancestry, or national origins among Hispanic or Latino participants and, early in the pandemic, among non-Hispanic Asian participants.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lee YH, Liu Z, Fatori D, et al. Association of Everyday Discrimination With Depressive Symptoms and Suicidal Ideation During the COVID-19 Pandemic in the All of Us Research Program. JAMA Psychiatry. 2022. PMID: 35895053. doi:10.1001/jamapsychiatry.2022.1973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。